Pathophysiology, diagnosis, and management of hepatic encephalopathy
- 839 Downloads
Hepatic encephalopathy (HE) is a common complication of cirrhosis of the liver. It is also extremely debilitating, with an untreated 3-year survival of only 23 %. While the exact pathophysiology of HE has yet to be elucidated, a number of contributing factors have been described. Abnormal levels and altered metabolism of ammonia play a central role. Recently, inflammation has also been identified as a contributor to HE. Improved understanding of the pathophysiology of HE is crucial, as current therapy centers on reduction of the body’s ammonia load. Lactulose is the first-line therapy for HE, with some antibiotics recently showing promise for improved outcomes in patients with HE. The role of anti-inflammatory therapies has yet to be evaluated.
KeywordsHepatic encephalopathy Ammonia Lactulose Antibiotics
The authors thank Dr Hector Baillie for reviewing the manuscript.
- Als-Nielsen B, Gluud LL, Gluud C (2004) Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev CD003044Google Scholar
- Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, Vilstrup H, Morgan MY (2013) The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 58:325–336PubMedCrossRefGoogle Scholar
- Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM (2012) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303:G675–G685PubMedCentralPubMedCrossRefGoogle Scholar
- Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M, Del Olmo JA, Ortega J, Martinez-Valls J, Serra MA, Cassinello N, Wassel A, Jorda E, Montoliu C (2012) Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 27:51–58PubMedCrossRefGoogle Scholar
- Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716–721PubMedCrossRefGoogle Scholar
- Kundra A, Jain A, Banga A, Bajaj G, Kar P (2005) Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raise intracranial tension. Clin Biochem 38:696–699PubMedCrossRefGoogle Scholar
- Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, Martines D, Abbiati R (1990) Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol 11:92–101PubMedCrossRefGoogle Scholar
- Poordad FF (2006) Review article: the burden of hepatic encephalopathy. Aliment pharmacol ther 25(Suppl. 1):3–9Google Scholar
- Riggio O, Ridola L, Pasquale C (2010) Hepatic encephalopathy therapy: an overview. World J Pharmacol Ther 1:54–63Google Scholar
- Vince A, Dawson AM, Park N, O’grady F (1973) Ammonia production by intestinal bacteria. Gut 14:171–177Google Scholar